AIM: Many perianal fistulae in @entity30 do not respond to conventional surgical and medical management and recurrence rates are high. The study evaluated the safety and feasibility of allogeneic adipose-derived stem cells for the treatment of @entity292 in @entity30 . METHOD: A multicentre, open-label, dose escalation pilot study was performed. The first three @entity1 (group 1) were administered 1  *  10(7) cells/ml based on the size of the @entity292 tract. Four  weeks later, after which time this dose had been confirmed to be safe, the next three @entity1 (group 2) were administered 3  *  10(7) cells/ml. The end-point was complete closure at 8  weeks after the injection. @entity1 who attended for the 8  week assessment were followed for an additional 6  months. RESULTS: There were no adverse events of Grade 3 or 4 severity and no adverse events related to the treatment with allogeneic adipose-derived stem cells. Two @entity1 in group 1 achieved complete closure of the @entity292 at month 4 and month 6, and one @entity1 in group 2 achieved complete closure at 8  weeks. The closure was sustained up to month 8 in all three of those @entity1 . CONCLUSION: These data suggest that allogeneic adipose-derived stem cells may be a feasible treatment option for @entity292 in @entity30 .

Allogeneic adipose-derived stem cells for the treatment of XXXX in @entity30 : a pilot clinical trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity292 :: ('MESH:D005402', 'Disease') :: ['fistula', 'perianal fistula'] @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]
@entity292 :: (MESH:D005402,Disease) :: ['perianal fistula']
